Reteplase biosimilar (Jiangsu Wuzhong)

瑞替普酶生物类似药（江苏吴中医药）

Report date: 2022/01/22 15:19:05

Base Information

Drug NameReteplase biosimilar (Jiangsu Wuzhong)
Drug Alias Name瑞替普酶生物仿制药（江苏吴中医药）
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzymeBiologics > Biosimilar
Mechanisms of ActionPlasminogen stimulants
TargetsPlasminogen
Therapy Area/IndicationsMyocardial Infarction
Global Approved IndicationsMyocardial Infarction
Approved Indications in ChinaMyocardial Infarction
Original Approved Country/TerritoryMainland China
Original Approved Date2009/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Wuzhong Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Wuzhong Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsMyocardial Infarction
Inactive IndicationsN/A

Other Information

ATC CodeB01AD07
Related LinksN/A